Technical Evaluation and Results of the Use of TREO® Modular Aortic Endografts for the Treatment of Abdominal Aortic Aneurysms

NCT ID: NCT06893952

Last Updated: 2025-03-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

209 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-04-30

Study Completion Date

2031-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a clinical investigation as part of the post-market clinical follow-up of the TREO® abdominal aortic graft in its initial use, French, observational, multicenter, non-randomized, single-arm. Information on patient's health and the implanted device will be collected over a period of 5 consecutive years. The data collected will be analyzed on the technical success and the absence of major events (death, stroke, myocardial infarction, visceral ischemia, paraplegia, respiratory failure, renal failure, intraoperative blood loss, thromboembolic event) and possible reinterventions related to the patient's operation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aortic Aneurysm Abdominal

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TREO Endograft

Post Market collection data in use of TREO modular endografts

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patient who has confirmed his/her non-opposition to the use of his/her data in the study.
2. Patient aged 45 years or older.
3. Patient with AAA with one of the following criteria:

* Maximum diameter ≥50 mm for women and ≥55 mm for men
* Rapid growth (≥5 mm in 6 months or ≥10 mm in 12 months)
* Unruptured AAA with clinical symptoms of abdominal pain
4. Adequate anatomy for TREO® stent graft implantation, including:

* Adequate iliac and femoral arteries for the modular system
* Suprarenal angle less than 45 degrees
* Infrarenal aortic neck greater than or equal to 10 mm in length with an angle less than 60° and an internal diameter of 17mm-32mm, or an infrarenal aortic neck greater than or equal to 15 mm in length with an angle between 60 and 75° and an internal diameter of 16mm-30mm
* Distal iliac sealing distance ≥ 10 mm and an iliac diameter between 8-13 mm or a distal iliac sealing distance ≥ 15 mm and a diameter between 13-21 mm
5. Ability to follow the entire protocol from 1 to 60 months
6. Life expectancy greater than 2 years

Exclusion Criteria

1. Patients refusing treatment and follow-up as part of the study
2. Infected or ruptured aneurysm
3. Associated aortic lesion (thoracic or thoracoabdominal aneurysm) requiring management
4. Renal failure defined by creatinine \> 2.5 mg/dL or patient in pre-dialysis status and impossibility of intervention with use of CO2 injection
5. New York Heart Association (NYHA) class IV
6. Aneurysmal, dissected distal implantation zone, or including calcifications and/or significant thrombus that could compromise sealing
7. Tortuous iliac and/or femoral access and/or including calcified stenosis
8. Systemic infection that could increase the risk of infection of the endoprosthesis
9. Pathology of the supporting tissues such as collagenosis (Marfan or Ehler-Danlos, etc.)
10. Known drug use
11. Known sensitivity or allergy to the materials to be implanted
12. Patients contraindicated for antiplatelet treatment
13. Patients with an uncontrolled hematological disorder or heparin-induced thrombocytopenia
14. Patients who are pregnant or planning to become pregnant
15. Patients considered hemodynamically unstable or requiring emergency treatment
16. Patients with severe arterial disease leading to a negative "outflow" that may degrade the permeability of implanted stents
17. Scheduled hybrid aortic technique (surgical and endovascular)
18. Patients with complex iliac access outside the manufacturer's indications and recommendations that may lead to procedural failure
Minimum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Vascutek Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RegisTREO _2024.01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Thoracoabdominal Aortic Aneurysms
NCT06267573 NOT_YET_RECRUITING